Orphan drug designation for pancreatic cancer candidate
January 2015
by  |  Email the author


CAMBRIDGE, Mass.—The U.S. Food and Drug Administration (FDA) has granted MM-141 orphan drug designation for the treatment of pancreatic cancer, Merrimack Pharmaceuticals Inc. reported recently. The investigational compound is a tetravalent bispecific antibody designed to block tumor survival signals by targeting receptor complexes containing IGF-1R and ErbB3. This designation grants Merrimack seven-year marketing exclusivity for MM-141 should the drug receive FDA approval. A Phase 2 study investigating MM-141 combined with nab-paclitaxel and gemcitabine in frontline pancreatic cancer is expected to start next year.
Dr. Ulrik Nielsen, Merrimack's chief scientific officer and co-founder, called the designation “an important regulatory advancement in the development of our clinical program,” adding that “We look forward to advancing the clinical development of MM-141 as we believe that it has the potential to significantly inhibit tumor survival signaling and address pathways of therapeutic resistance in this indication.”

Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.